ACTH-treated mice showed improved MS clinical symptoms by downregulating the levels of IL-6, but with increased Treg cells in the lamina propria and a low population of CD4+ and γδ IL-17 cells in the central nervous system [63]. This evidence concerns the gene CD4 and myeloid sarcoma.